Dongwu Securities released a research report on April 11 stating that it gave Bailey Tianheng (688506.SH) a purchase rating. The main reasons for the rating include: 1) traditional formulations nurture innovation, paving the way for Baili Tianheng; 2) BL-B01D1 pioneered a dual-antibody ADC and worked with BMS to create the next blockbuster; 3) ADC and multi-antibody platforms are globally differentiated, and the echelon product portfolio is gradually building a global Biopharm. (Mainichi Keizai Shimbun)
东吴证券4月11日发布研报称，给予百利天恒（688506.SH）买入评级。评级理由主要包括：1）传统制剂厚积薄发孕育创新，为百利天恒铺垫全球化路径；2）BL-B01D1 为首创双抗 ADC，携手 BMS 共同打造下一个重磅炸弹；3）ADC及多抗平台具备全球差异化，梯队产品组合逐步打造全球Biopharm。（每日经济新闻）
Dongwu Securities released a research report on April 11 stating that it gave Bailey Tianheng (688506.SH) a purchase rating. The main reasons for the rating include: 1) traditional formulations nurture innovation, paving the way for Baili Tianheng; 2) BL-
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.